Veronate (Inhibitex).
Inhibitex, under license from BioResearch, is developing Veronate, an antibody-based immunotherapy for the potential prevention of Staphylococcus epidermidis, Staphylococcus aureus and Candida infections in very-low-birth-weight infants. Phase III clinical trials of Veronate are ongoing.
Kaufman
David
D
University of Virginia Health System, Department of Pediatrics, Charlottesville 22908, USA. DAK4R@virginia.edu
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002175:Candida / Q000276:immunology; D002177:Candidiasis / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007262:Infusions, Intravenous; D016032:Randomized Controlled Trials as Topic; D018805:Sepsis / Q000517:prevention & control*; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013210:Staphylococcus / Q000276:immunology
D000890:Anti-Infective Agents; D016756:Immunoglobulins, Intravenous; C511124:Veronate